BRCA1 Protein

• 

  Subject Areas on Research

  • A computational method to classify variants of uncertain significance using functional assay data with application to BRCA1. 
  • An inevitable dilemma: prenatal testing for mutations in the BRCA1 breast-ovarian cancer susceptibility gene. 
  • Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer. 
  • BRCA testing within the Department of Veterans Affairs: concordance with clinical practice guidelines. 
  • BRCA1 expression is not directly responsive to estrogen. 
  • BRCA1 immunohistochemistry in a molecularly characterized cohort of ovarian high-grade serous carcinomas. 
  • BRCA1 is required for common-fragile-site stability via its G2/M checkpoint function. 
  • BRCA1 mutations in primary breast and ovarian carcinomas. 
  • BRCA1 testing in families with hereditary breast-ovarian cancer. A prospective study of patient decision making and outcomes. 
  • Breast cancer risk factors differ between Asian and white women with BRCA1/2 mutations. 
  • Cell cycle control of BRCA2. 
  • Comparing Coordinated Versus Sequential Salpingo-Oophorectomy for BRCA1 and BRCA2 Mutation Carriers With Breast Cancer. 
  • Cost-effectiveness of BRCA1 and BRCA2 mutation testing to target PARP inhibitor use in platinum-sensitive recurrent ovarian cancer. 
  • Detection of BRCA1 mutations in women with early-onset ovarian cancer by use of the protein truncation test. 
  • Development of human protein reference database as an initial platform for approaching systems biology in humans. 
  • Evaluation of established breast cancer risk factors as modifiers of BRCA1 or BRCA2: a multi-center case-only analysis. 
  • Human ovarian cancer of the surface epithelium. 
  • Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. 
  • Identification of a new subclass of Alu DNA repeats which can function as estrogen receptor-dependent transcriptional enhancers. 
  • Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. 
  • Identification of six new susceptibility loci for invasive epithelial ovarian cancer. 
  • Improving indel detection specificity of the Ion Torrent PGM benchtop sequencer. 
  • Involvement of Brca1 in S-phase and G(2)-phase checkpoints after ionizing irradiation. 
  • Involvement of the cohesin protein, Smc1, in Atm-dependent and independent responses to DNA damage. 
  • Managing hereditary ovarian cancer risk. 
  • Metastasizing patent claims on BRCA1. 
  • Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis. 
  • Phosphorylation of SMC1 is a critical downstream event in the ATM-NBS1-BRCA1 pathway. 
  • Phosphorylation of serine 1387 in Brca1 is specifically required for the Atm-mediated S-phase checkpoint after ionizing irradiation. 
  • Pioneering geneticist Mary-Claire King receives the 2014 Lasker~Koshland Special Achievement Award in Medical Science. 
  • Probing structure-function relationships in missense variants in the carboxy-terminal region of BRCA1. 
  • Refining the role of BRCA1 in combating oxidative stress. 
  • Regulation of BRCA1 phosphorylation by interaction with protein phosphatase 1alpha. 
  • Repair versus Checkpoint Functions of BRCA1 Are Differentially Regulated by Site of Chromatin Binding. 
  • Risk factors for ovarian cancers with and without microsatellite instability. 
  • Screening for the breast cancer gene (BRCA1) using a biochip system and molecular beacon probes immobilized on solid surfaces. 
  • Spatial organization of the mammalian genome surveillance machinery in response to DNA strand breaks. 
  • Surface-enhanced Raman scattering substrate based on a self-assembled monolayer for use in gene diagnostics. 
  • The genetic attributable risk of breast and ovarian cancer. 
  • Two identical triplet sisters carrying a germline BRCA1 gene mutation acquire very similar breast cancer somatic mutations at multiple other sites throughout the genome. 
  • Yeast screens identify the RNA polymerase II CTD and SPT5 as relevant targets of BRCA1 interaction. 
• 

  Keywords of People

  • Berchuck, Andrew, James M. Ingram Professor of Gynecologic Oncology, Obstetrics and Gynecology, Gynecologic Oncology
  • Moorman, Patricia Gripka, Professor in Community and Family Medicine, Duke Cancer Institute